enVVeno Medical Corp(NVNO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -23.45 | Insider Own | 2.93% | Shs Outstand | 0.7M | Perf Week | 6.45% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.74% | Shs Float | 0.7M | Perf Month | -10.42% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 12.77% | Short Float | 1.76% | Perf Quarter | -35.19% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | -9.8% | Short Ratio | 0.41 | Perf Half Y | -30.88% |
| Sales | 0.00B | P/B | 0.3 | EPS next 5Y | - | ROA | -60% | Short Interest | 0.01M | Perf YTD | -36.1% |
| Book/sh | 24.32 | P/C | 0.27 | EPS past 3/5Y | 24.52% 34% | ROE | -67.11% | 52W High | -72.37% ($25.97) | Perf Year | -71.11% |
| Cash/sh | 26.6 | P/FCF | - | Sales past 3/5Y | - | ROIC | -92.02% | 52W Low | 10.05% ($6.52) | Perf 3Y | -95.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 40.73% | Gross Margin | - | Volatility(W/M) | 8.34% 9.23% | Perf 5Y | -97.71% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.7 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.35 | EPS Q/Q | 20.17% | Profit Margin | - | RSI (14) | 42.56 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.35 | Sales Q/Q | - | SMA20 | -3.37% ($7.43) | Beta | 1.37 | Target Price | $30 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/10/30 | SMA50 | -18.69% ($8.83) | Rel Volume | 3.67 | Prev Close | $6.87 |
| Employees | 33 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -92.35% - | SMA200 | -30.06% ($10.27) | Avg Volume(3M) | 0.03M | Price | $7.18 |
| IPO | 2018/5/31 | Option/Short | No/Yes | Trades | 1196 | Volume | 106,314 | Change | 4.44% |
🫀 This is a small, early clinical/commercial-stage medical device company developing the <b>surgical prosthetic venous valve (VenoValve®)</b> and the next-generation transcatheter valve (enVVe), both targeting chronic venous insufficiency (CVI) of the deep veins. The company has received the FDA’s Breakthrough Device designation, but in August 2025 it was issued a not-approvable letter for the VenoValve PMA review, placing it in a restructuring phase.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded more than usual. That is 367% of its average volume.
NVNO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.7%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #124 of 140 in the industry
Based on market cap of $5M.
INBS#121 Intelligent Bio Solutions Inc $6M PER - 
VNRX#122 VolitionRX Ltd $5M PER - 
TNON#123 Tenon Medical Inc $5M PER - NVNO#124 enVVeno Medical Corp $5M PER - 
WOK#125 Work Medical Technology Group Ltd $5M PER - 
FAQ
What kind of company is NVNO?
NVNO belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NVNO?
The market cap of NVNO is approximately $5M, ranking 5,622 within its sector.
What is the 52-week high and low for NVNO?
NVNO has recorded a 52-week high of $25.97 and a low of $6.52.
